ArticleEuropean journal of nuclear medicine and molecular imaging2026
Bridging the gap to clinical translation: the advanced role of PET molecular imaging in stem cell therapy.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In the past few decades, stem cell therapy has achieved remarkable progress in preclinical and clinical trials, especially for treating major diseases, such as stroke, Parkinson’s disease (PD), myocardial infarction, diabetes, etc (Temple, Cell Stem Cell 30:512-29, 2023). However, the current challenge in clinical translation lies in the difficulty in non-invasively, dynamically, and quantitatively assessing the survival, proliferation, homing, migration, and function of stem cells in vivo. This lack of assessment leads to inconsistent therapeutic effects, unclear mechanisms, and difficulties in optimizing dosages (Hussen et al., Int J Surg. 110:8002-24, 2024). Positron emission tomography (PET), with its superior sensitivity and quantitative capability, is an ideal technology to visualize and monitor stem cells in vivo. Also, as an advanced tool of precision medicine, PET molecular imaging can accurately evaluate the therapeutic efficacy and predict the outcome of stem cell therapy (Cen et al., Eur J Nucl Med Mol Imaging 53:71-92, 2025). It integrates individual features, cellular properties, and dynamic biomarkers, achieving personalized strategies of stem cell therapy with maximized efficacy and minimized risks in clinical practice. Thus, PET plays a key role in bridging the gap to clinical translation and accelerate clinical practice of stem cell therapy.
Indexed as
Identifiers
41876863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.